SINGAPORE — Life Technologies Corporation( https://www.lifetechnologies.com/us/en/home.html ) today announced that the Philippine Genome Center (PGC) has launched its DNA Sequencing Core Facility equipped with a genetic analysis workflow system by Life Technologies, including the 3730xl DNA Analyzer, Ion PGM(TM)and Ion Proton(TM)Systems for sequencing genes to genomes, Ion AmpliSeq(TM) Gene Panels and a 7500 Fast Real-Time PCR System and auxiliary products.

PGC’s state-of-the-art facility, which is located on the University of the Philippines (UP), Diliman campus, will use the entire product line to provide DNA sequencing and bioinformatics services to clients, as well as pursue research in human health and agriculture. The PGC has already started on a project to improve sugar cane varieties by enabling farmers to genetically differentiate plants of interest against others, and another project to introduce a new variety of sugar cane. The PGC is also working to re-populate the country’s dwindling coconut tree population by identifying genetic markers for the best coconuts that will fit the countries’ environment and needs.

“The DNA Sequencing Core Facility of PGC is an important step forward for the Philippines, which must continue to invest in science and technology to realize its true potential, as well as for UP, which has taken another critical step toward becoming a research university,” said Dr. Cynthia Saloma, Program Director of the PGC DNA Sequencing Core Facility. “We are truly grateful for the financial support of Philippine Council for Industry, Energy and Emerging Technology Research and Development and for the partnership with Life Technologies in helping us on our journey. The company’s cutting-edge technology and its outstanding support staff have been invaluable in getting the new facility up and running and we look forward to working closely with them in the future.”

“The PGC represents a key opportunity for scientists in the Philippines and throughout Southeast Asia who will have access to this amazing facility to support their research” said Joydeep Goswami, President of Asia Pacific and Japan of Life Technologies. “Our partnership with the PGC is another example of our commitment to the region and to ensure that every scientist, regardless of geography, has access to the tools and support they need to keep their citizens healthy, well-fed, safe and to innovate.”

The Ion PGM(TM), Ion Proton(TM)Systems and Ion AmpliSeq(TM) Panels are For Research Use Only. Not for use in diagnostic procedures.About Life Technologies

Life Technologies Corporation( https://www.lifetechnologies.com/us/en/home.html?cid=fl-home%3fCID=fl-home ) (LIFE) is a global biotechnology company that is committed to providing the most innovative products and services to leading customers in the fields of scientific research, genetic analysis and applied sciences. With a presence in more than 180 countries, the company’s portfolio of 50,000 end-to-end solutions is secured by more than 5,000 patents and licenses that span the entire biological spectrum — scientific exploration, molecular diagnostics, 21st century forensics, regenerative medicine and agricultural research. Life Technologies has approximately 10,000 employees and had sales of $3.8 billion in 2012.

Life Technologies’ Safe Harbor Statement

This press release includes forward-looking statements about our anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and Life Technologies’ plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words “believe,” “plan,” “intend,” “anticipate,” “target,” “estimate,” “expect” and the like, and/or future tense or conditional constructions (“will,” “may,” “could,” “should,” etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by Life Technologies with the Securities and Exchange Commission. Life Technologies undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.

Life Technologies Media Contact:

Atsuko Igawa

Tel: +81-36832-9446

atsuko.igawa@lifetech.com